Daratumumab, an anti‐CD38 antibody widely used in multiple myeloma, has previously been shown to improve autoimmune cytopenias [34] and can induce long‐term remission for ITP refractory to splenectomy and corticosteroids [35]. Here, CD38 is linked to plasma cell myeloma.